Abstract
Pagoclone is a cyclopyrrolone GABAA receptor modulator under development by Indevus for the potential treatment of panic and anxiety disorders. Indevus initiated phase II/III trials in November 1996. Pfizer had initiated a phase III trial for panic disorder in August 2000 but discontinued development of the compound in June 2002.
MeSH terms
-
Animals
-
Anti-Anxiety Agents / adverse effects
-
Anti-Anxiety Agents / pharmacology*
-
Anti-Anxiety Agents / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Humans
-
Isoindoles
-
Naphthyridines / adverse effects
-
Naphthyridines / pharmacology*
-
Naphthyridines / therapeutic use
-
Panic Disorder / drug therapy
-
Structure-Activity Relationship
Substances
-
Anti-Anxiety Agents
-
Isoindoles
-
Naphthyridines
-
pagoclone